Disclosed is a site-specific, pharmaceutical composition comprising: (a) a therapeutic amount of at least one hemostatic agent, wherein at least one such hemostatic agent is an anti-fibrinolytic agent, wherein the therapeutic amount is effective to reduce hematoma expansion or recurrent bleeding resulting from a hemorrhagic condition in brain, when compared to a non-treated control and (b) a pharmaceutically acceptable carrier, wherein the carrier comprises a plurality of microparticles comprising the therapeutic amount of the hemostatic agent dispersed throughout each microparticle, in a core of the microparticle surrounding by a coating, adsorbed into the particles, or a combination thereof, and the microparticles provide sustained release of the hemostatic agent from the microparticles at the implant site to maintain a high concentration of the hemostatic agent locally and lower concentrations in the rest of the body, thus decreasing risk of unwanted systemic side effects, wherein the composition is formulated for deposition in or on a biodegradable implant at an implant site in a cavity or space within the human brain occupied by a hematoma or in a subdural space on the surface of the brain, wherein the implant is in a form of a sheet or a string and for flowability of the hemostatic agent in cerebrospinal fluid from the implant site to a site of bleeding in or on the brain.
